AbstractöThe ventrolateral medulla has a critical role in the generation and patterning of respiration via an extensive network of respiratory neurones. We have investigated the e¡ects of activating purinergic P2 receptors within the ventrolateral medulla of the anaesthetised rat on the overall pattern of respiratory activity. In addition, using immunohistochemical techniques, we have identi¢ed the subtypes of P2X receptors in the ventrolateral medulla. Unilateral microinjection of ATP into the ventrolateral medulla reduced in a dose-dependent manner, or abolished, resting phrenic nerve discharge recorded as an indication of central inspiratory drive. ATP also elicited increases in blood pressure and variable changes in heart rate. These e¡ects were mimicked by microinjection of the P2X receptor agonist K,L-methylene ATP into the ventrolateral medulla. Whilst microinjection of suramin, a P2 receptor antagonist, had no e¡ect on resting cardiorespiratory variables it blocked the respiratory and cardiovascular e¡ects of ATP microinjected into the ventrolateral medulla. Immunohistochemical staining using IgG antibodies showed that P2X 1 , P2X 2 , P2X 5 and P2X 6 , but not P2X 3 , P2X 4 or receptor subunits were localised in the rostral ventrolateral medulla.
ATP, acting via P2X ion channel receptors, is a fast neurotransmitter within the CNS (Jahr and Jessel, 1983; Edwards et al., 1992; Day et al., 1993; Torres et al., 1999) . In recent years, there has been a growing body of evidence that ATP acting at P2X receptors within the medulla oblongata can modulate cardiovascular activity (Phillis et al., 1997; Horiuchi et al., 1999; Ralevic et al., 1999) . In particular, we have shown that ATP applied iontophoretically to presumptive vasomotor neurones within the ventrolateral medulla (VLM) evokes a potent excitatory e¡ect . This may explain why activation of P2X receptors in VLM evokes a large increase in arterial pressure, accompanied by a signi¢cant increase in sympathetic nerve activity (Sun et al., 1992; Horiuchi et al., 1999) .
However, this area of the VLM also contains an extensive respiratory network, including the pre-Bo « tzinger and Bo « tzinger complexes and the nucleus ambiguus (Richter, 1996) . This`ventral respiratory group' has a fundamental role in controlling the activity of the respiratory muscles. Whilst it is clear that ATP can act on the cardiovascular neurones in this area, the possibility that ATP might also modulate respiratory activity within the VLM has not been fully addressed. However, this prospect seems likely since we have recently illustrated that P2X receptors within the VLM are an important component in carbon dioxide-mediated changes in respiration .
In this study we have addressed the question of whether ATP receptors within the VLM are involved in respiratory control. First, we have investigated the e¡ects of microinjection of ATP and its stable analogue K,L-methylene ATP (K,L-meATP) into the pre-Bo « tzinger and Bo « tzinger complexes on both cardiovascular and respiratory activity simultaneously. In addition, we have employed immunohistochemical techniques in order to visualise, and localise, the P2X receptor subtypes present within the VLM.
Some of these results have been reported previously in preliminary abstracts .
EXPERIMENTAL PROCEDURES
In vivo studies General methods. All studies were carried out on male Sprague^Dawley rats supplied by the Royal Free and University College Medical School, London, UK (275^320 g) anaesthetised initially with pentobarbital sodium (Sagatal1, MaypBaker, UK, 60 mg/kg, i.p.), with anaesthesia being maintained with supplemental doses as required (10 mg/kg, i.v.) . The depth of anaesthesia was assessed by monitoring the stability of arterial blood pressure (ABP), heart rate (HR) and phrenic nerve discharge (see below), and the minimal e¡ects on cardiovascular variables of a pinch to the paw. All of the following procedures and protocols were carried out in accordance with the UK Animals (Scienti¢c Procedures) Act, 1986. All e¡orts were made to minimise animal su¡ering and to use only the number of animals necessary to produce reliable scienti¢c data.
The femoral artery and vein were cannulated for measurement of ABP and administration of supplemental anaesthetic respectively. A cannula was placed into the trachea, and the animal ventilated arti¢cially with oxygen-enriched air (Harvard ventilator, model 683). The animal was then paralysed with gallamine triethiodide (Flaxedil1, 10 mg/kg, then 1^2 mg/kg/h, i.v.). The animal was placed in a stereotaxic frame and an occipital craniotomy performed. The cerebellum was partially removed to expose the dorsal surface of the lower brainstem. The activity of the phrenic nerve was recorded as an indication of central respiratory drive. The nerve was dissected, cut peripherally and prepared for recording. The signal was ampli¢ed (U10 000), ¢ltered (500^1500 Hz) and recti¢ed and smoothed (d = 100 ms); (Neurolog system, Cambridge Electronic Design, Cambridge, UK). Arterial blood samples were taken to ensure levels of oxygen, carbon dioxide and pH were kept within physiological levels (PaO 2 , 90^100 mm Hg; PaCO 2 , 35^45 mm Hg; pH, 7.35^7.4; Corning Blood Gas Analyser (Model 158), Corning, UK). A ¢ve-barrelled micropipette, prepared for microinjection (tip size 40^60 Wm) was placed in the VLM using stereotaxic coordinates: 2.3 mm rostral to obex, 2 mm lateral to midline and 2.8^3 mm ventral from the surface (Paxinos and Watson, 1998) .
Protocol. Unilateral microinjections (50 nl) of glutamate (0.2 M, pH 7.4) were made into the right or left VLM using pressure. The injection of drug was monitored using a dissecting microscope with a calibrated micrometre disk and made over 5 s. If a brisk cardiorespiratory response was observed upon injection of glutamate, a control response to the injection of ATP (2 mM, pH 7.4, 50 nl) into the same site was obtained. Once levels of cardiovascular and respiratory variables had returned to baseline, a higher dose of ATP (20 mM, pH 7.4, 50 nl) was microinjected into the same site. Once levels of cardiovascular and respiratory variables had again returned to baseline the P2 receptor antagonist suramin (0.02 M, pH 7.4, 50 nl) was microinjected into the same site. After 5 min, the lowest dose of ATP was again microinjected into this site. Once stable baselines had resumed, the higher dose of ATP was again tested at the same site.
In a di¡erent group of animals the P2X agonist K,L-meATP (0.2^2 mM, pH 7.4, 50 nl) was microinjected into the left or right VLM. Since this compound is known to cause receptor desensitisation, in some cases we repeated the microinjection of K,L-meATP into the same site after all variables had returned to baseline levels and not less than 10 min had elapsed since the previous injection. The sites of microinjection were marked by pressure injection of Pontamine Sky Blue dye.
We have shown previously that vehicle injections into this area of the brainstem are ine¡ective (Thomas and Spyer, 1996) .
Histology. At the end of each experiment the brain was removed, ¢xed in 10% formal saline, frozen, sectioned serially (100 Wm) and counterstained with Neutral Red. Microinjections were visualised using a light microscope and mapped using a stereotaxic atlas (Paxinos and Watson, 1998) .
Data recording and analysis. Records of ABP, neuronal activity, phrenic nerve activity and integrated phrenic nerve activity were stored on computer and analysed using Spike 2 software (Cambridge Electronic Design). HR was calculated o¡-line from the blood pressure recording. Levels of mean ABP, HR and frequency of phrenic nerve discharge were measured immediately before microinjection of ATP or K,L-meATP and compared to the maximum response during drug application. The responses before and after suramin were compared using analysis of variance (ANOVA) with post-hoc Bonferroni's test for multiple comparisons. All data are presented as mean þ S.E.M. In all instances P 6 0.05 was considered statistically signi¢cant.
Drugs. ATP (disodium salt), L-glutamate, K,L-meATP (lithium salt) and Pontamine Sky Blue were purchased from Sigma (Poole, UK). Suramin was from Bayer. Pontamine Sky Blue was dissolved in 0.2 M sodium acetate. All other drugs were dissolved in 1 mM saline. pH was adjusted by adding 0.5 M NaOH or 0.5 M HCl. Purine compounds were used at concentrations used by others and us previously (Sun et al., 1992; .
Immunohistochemical studies
Tissues. Male rats (275^320 g) were killed by an overdose of pentobarbital sodium given i.p. The brainstem was removed and immersion-¢xed overnight at 4³C in 4% paraformaldehyde containing 0.2% of a saturated solution of picric acid in 0.1 M phosphate bu¡er. The tissues were washed in 7% sucrose and left overnight in this solution at 4³C.
The tissues were then embedded in OCT compound (BDH/ Merck, Leicestershire, UK) and frozen in isopentane pre-cooled in liquid nitrogen. Consecutive sections of 10 Wm were taken using a cryostat (Reichert Jung CM1800), collected on gelatincoated slides and air-dried at room temperature. The slides were stored at 320³C and allowed to return to room temperature for at least 10 min prior to use. One in 10 sections was taken as an overview and stained with Cresyl Violet according to the atlas of Paxinos and Watson (1998) .
Development of primary antibodies. The immunogens used were peptides corresponding to 15 receptor type-speci¢c amino acids in the C-terminal region of the receptor. The peptide sequences are as follows: P2X 1 , amino acids 385^399 (ATSSTLGLQENMRTS); P2X 2 , amino acids 458^472 (QQDSTSTDPKGLAQL); P2X 3 , amino acids 383^397 (VEKQSTDSGAYSIGH); P2X 4 , amino acids 374^388 (YVE-DYEQGLSGEMNQ); P2X 5 , amino acids 437^451 (RENAIVNVKQSQILH); P2X 6 , amino acids 357^371 (EAG-FYWRTKYEEARA). The synthetic peptides were covalently linked to keyhole limpet haemocyanin and the conjugate was administered to rabbits at monthly intervals (performed by Research Genetics, Huntsville, AL, USA).
Immunoglobulin G (IgG) fractions were isolated from the immune and preimmune sera (P2X 1À7 ) following the method of Harboe and Ingild (1973) . The protein concentration was determined at 280 nm using an extinction factor of 1.43 for 1 mg/ml. The speci¢city of the antibodies was veri¢ed by immunoblotting with membrane preparations from CHO-K1 cells expressing the cloned P2X 1À7 receptors. Immunoblotting studies have shown that anti-P2X 1À7 antibodies speci¢cally recognise the recombinant receptors expressed in CHO-K1 cells (Oglesby et al., 1999) . Pre-absorption of the antibodies with excess of the appropriate synthetic peptide used for generation of the antibodies eliminated immunoreactivity.
Immunohistochemistry. The avidin^biotin^peroxidase complex technique was employed according to the protocol described previously (Llewellyn-Smith et al., 1992 . The slide-mounted sections were rinsed in phosphate-bu¡ered saline (PBS) to remove any OCT compound. To inactivate endogenous peroxidase, the sections were then treated with 20% meth-NSC 5204 5-11-01 T. Thomas et al. 482 anol containing 0.4% hydrogen peroxide in PBS for 10 min. Non-speci¢c binding sites were blocked by a 20-min incubation with 10% normal horse serum (NHS) in PBS containing 0.05% merthiolate. The P2X antibodies were diluted to 5 Wg/ml (determined as optimal by prior titration) with 10% NHS containing 0.2% Triton X-100, and the sections were incubated with the primary antibodies overnight at room temperature. The secondary antibody was a biotinylated donkey anti-rabbit IgG (Jackson Immunoresearch, Luton, UK) used at a dilution of 1:500 for 1 h, followed by the ExtrAvidin peroxidase conjugate (Sigma, St. Louis, MO, USA) at 1:1500 for 1 h.
To visualise the reaction product, the nickel-diaminobenzidine enhancement technique was used. The specimens were dehydrated to xylene and mounted in Eukitt (BDH/Merck, Leicestershire, UK). Controls were performed with pre-immune IgG and with the P2X antibodies pre-absorbed with the homologous peptides; no staining was observed. The results were documented using the Edge R400 high-de¢nition light microscope (Edge Scienti¢c Instruments, Santa Monica, CA, USA) and Kodak TMX 100 ¢lm.
RESULTS

Microinjection studies
Baseline levels of ABP, HR and frequency of phrenic nerve bursts were 117 þ 4 mm Hg, 339 þ 11 beats/min and 68 þ 4 bursts/min respectively (n = 18). Microinjection of glutamate (0.2 M) into the VLM evoked a short-lasting increase in ABP (27 þ 6 mm Hg, P 6 0.05) and a reduction, or cessation, of phrenic nerve discharge (386 þ 8%, P 6 0.01) (n = 18). Glutamate evoked inconsistent e¡ects on HR. These responses to glutamate injection indicated that the observed e¡ects of stimulation in this region were a result of excitation of perikarya but not ¢bres of passage (Fries and Zieglgansberger, 1974) .
Microinjection of the low dose of ATP (2 mM) into the same sites evoked an increase in ABP (n = 6, Table 1 and Fig. 1 ). ATP had variable e¡ects on HR evoking tachycardia in four cases and bradycardia in two cases (n = 6, Table 1 and Fig. 1 ). In addition, ATP produced a marked reduction in, or abolished, phrenic nerve activity (n = 6, Table 1 and Fig. 1 ). In four of six cases, subsequent microinjection of the larger dose of ATP (20 mM) into the same site evoked a larger increase in ABP. There were still variable changes in HR in response to the higher dose of ATP ( Fig. 1 and Table 1) .
Microinjection of the P2X receptor agonist K,LmeATP (0.2^2 mM) into the VLM produced qualitatively similar e¡ects to ATP (n = 11). The lowest dose of K,L-meATP (0.2 mM) evoked an increase in ABP, a tachycardia and a fall in phrenic nerve discharge which resulted in apnoea in six cases (see Table 2 and Fig. 2 ). Upon subsequent microinjection of a higher dose of K,LmeATP (1.25 mM) into the same site, a larger cardiorespiratory response was only seen in three of nine cases. In the remaining six cases, a smaller increase in ABP was observed illustrating desensitisation of this component of the response to K,L-meATP (Table 2 and Fig. 2 ). The e¡ects on HR and phrenic frequency were no di¡erent to those evoked by the lower dose. The changes in ABP, HR and phrenic activity evoked by K,L-meATP were further reduced in four of six cases upon subsequent microinjection of a third, higher, dose (2 mM; see Table 2 for mean responses).
Microinjection of the P2 receptor antagonist suramin (0.02 M, n = 6) had no signi¢cant e¡ect on baseline levels of ABP (101 þ 10 vs. 113 þ 13 mm Hg), HR (346 þ 17 vs. 354 þ 16 beats/min) and phrenic nerve activity (82 þ 10 vs. 86 þ 4 bursts/min). The cardiorespiratory responses Table 1 . Cardiovascular and respiratory responses to microinjection of ATP into the VLM 2 mM ATP (n = 6) 20 mM ATP (n = 6) % change in ABP (mm Hg) 11 þ 2** 27 þ 7* % change in HR (beats/min) 33 þ 4 9 þ 6 % change in respiratory frequency (phrenic bursts/min) 363 þ 20* 364 þ 18** *P 6 0.05, **P 6 0.01, signi¢cant di¡erence from baseline levels. evoked by glutamate microinjection were also una¡ected by suramin (Fig. 3) . However, suramin blocked the inhibitory e¡ects of both the low and high doses of ATP on phrenic nerve activity (P 6 0.05, n = 6, Fig. 3 ). The mean increases in ABP and changes in HR evoked by low doses of ATP were also reduced by suramin at this dose (Fig. 3) . Since K,L-meATP caused desensitisation of the evoked responses, we were unable to investigate the e¡ects of suramin on those responses. Histological analysis indicated our microinjections were made within the VLM in the pre-Bo « tzinger and Bo « tzinger complexes (Fig. 4) .
Immunohistochemical studies
Immunohistochemistry was carried out using P2X 1À6 antibodies. Reactivity within the rostral VLM was seen with P2X 1 , P2X 2 , P2X 5 and P2X 6 . On the other hand, there was no reaction in the rostral VLM with the other P2X receptor subtypes, i.e. P2X 3 and P2X 4 . However, we did observe P2X 3 and P2X 4 reactivity in more caudal and medial regions of the ventral medulla, in the lateral paragiganticellular nucleus (Paxinos and Watson, 1998) .
P2X 1 immunoreactivity was present within the VLM but did not extend extensively in a rostro-caudal aspect. It was contained at a level 3.30^3.72 mm caudal to the interaural line. This region overlaps the so-called preBo « tzinger complex (Paxinos and Watson, 1998 ). The Table 2 ). In this case a second injection of a larger dose of K,LmeATP (1.25 mM) did not evoke changes in the cardiovascular or respiratory variables, indicating desensitisation of the responses. T. Thomas et al. 484 cell bodies showed varying degrees of immunoreactivity but reactivity was particularly strong in the smaller cells localised towards the ventral surface of the medulla (see Fig. 5A ).
P2X 2 immunohistochemistry was observed in the larger cells in more dorsal regions of the rostral VLM around the nucleus ambiguus (Fig. 5) . There was still, however, some immunoreactivity at the ventral surface of the medulla.
There was a strong immunoreaction to P2X 6 antibodies within the VLM (Fig. 6 ) and the reactivity extended from very caudal regions of the ventral medulla (3.72 mm caudal of the interaural line) rostrally to the retrofacial nucleus, which overlaps the Bo « tzinger complex (Paxinos and Watson, 1998) . At very caudal levels, P2X 6 reactivity was also observed medially in the lateral paragiganticellular nucleus. In the rostral VLM there was strong P2X 6 reactivity in the large cells of the retrofacial nucleus (2.80 mm caudal to interaural line). Short cell processes also showed immunoreaction (Fig. 6) and again, the strongest reaction was in small neurones close to the ventral surface of the section (Fig. 6 ). Immunoreaction was also observed in the area of the nucleus ambiguus (Fig. 6) . P2X 1 , P2X 2 and P2X 6 antibodies pre-absorbed with an excess of the corresponding conjugated peptide used for immunisation lost all reactivity (e.g. Fig. 5F ).
DISCUSSION
These studies con¢rm the presence of P2X purinoceptors in the VLM of the rat and indicate that activation of these receptors has a profound e¡ect on respiratory activity. In addition to the pronounced e¡ects on respiration, microinjection of ATP and K,L-meATP elicited an increase in both ABP and HR as reported previously (Sun et al., 1992; Horiuchi et al., 1999) . It is possible that our microinjections may have a¡ected the neurones of the external formation of the nucleus ambiguus, which contains vagal parasympathetic preganglionic neurones. The P2X 6 immunoreactivity in the nucleus ambiguus might therefore explain some of the variability of the HR responses induced by ATP. A recent study in the rabbit showed that the pressor e¡ects of K,L-meATP are accompanied by a signi¢cant increase in sympathetic nerve activity (Horiuchi et al., 1999) . This is in accordance with our observation that ATP excites presumptive vasomotor neurones within the ventral medulla of the rat . However, in this study we have additionally recorded phrenic nerve activity as an indication of central respiratory drive. Microinjections of ATP and K,L-meATP both produced a fall in ventilatory drive, which at higher doses resulted in expiratory apnoea. Histological analysis revealed that our microinjections were concentrated within the Bo « tzinger and pre-Bo « tzinger complexes. Studies in the rat have shown that there are predominantly expiratory neurones in the Bo « tzinger complex (80%) and that at least more than half of the neurones in the pre-Bo « tzinger complex are expiratory or of the phase spanning IE (inspiratory o¡-switch) type (Sun et al., 1998) . Our previous electrophysiological data indicate that whilst ATP causes a generalised excitation of respiratory neurones within the VLM, irrespective of neuronal type and whether they are associated with driving inspiration or expiration, ATP was more e¡ective in increasing activity in post-inspiratory and expiratory neurones than inspiratory neurones . This obser- Fig. 4 . Distribution of histologically determined sites at which microinjections were made in the VLM (see Histology section for details). Note that microinjections and recordings were not restricted to one particular side of the brainstem as illustrated here for clarity. Distances are from bregma (Paxinos and Watson, 1998) . NTS, nucleus tractus solitarius; Amb, nucleus ambiguus; Bo, Bo «tzinger complex; PrBo, Pre-Bo « tzinger complex. Table 2 . Cardiovascular and respiratory responses to microinjection of K,L-meATP into the VLM
% change in ABP (mm Hg) 15 þ 4** 7 þ 2* 6 þ 7 % change in HR (beats/min) 4 þ 2* 4 þ 2* 3 þ 1 % change in respiratory frequency (phrenic bursts/min) 366 þ 14*** 357 þ 15** 322 þ 16 *P 6 0.05, **P 6 0.01, ***P 6 0.001, signi¢cant di¡erence from baseline levels; P 6 0.05, signi¢cant di¡erent between middle and lower dose of K,L-meATP.
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Purinergic signalling and respiration 485 vation, together with the fact that ATP had a greater excitatory e¡ect during the expiratory phase than during the inspiratory phase of discharge of pre-inspiratory neurones, might account for the expiratory apnoea that was produced when P2 receptor agonists were microinjected grossly into the Bo « tzinger and pre-Bo « tzinger complexes in the present study. Our observation that injections of suramin into the ventral medulla had no e¡ect on baseline levels of ABP and HR con¢rms the results of others (Horiuchi et al., 1999) . Whilst our unilateral injections of suramin were able to block the e¡ects of ATP on respiratory drive they had no e¡ect on baseline levels of respiratory activity. However, we have shown recently that bilateral microinjections of suramin into the VLM reduce resting phrenic nerve discharge suggesting that ATP has a role in determining the level of resting respiratory drive in the anaesthetised rat .
The fact that prior microinjection of the P2 receptor antagonist suramin blocked the ATP-evoked e¡ects on ventilatory drive suggests an involvement of P2 purinoceptors. This observation also makes it unlikely that the e¡ects of ATP on respiratory drive can be attributed to its breakdown product adenosine which is known to have an inhibitory e¡ect on respiration (Herlenius et al., 1997) . Adenosine receptors are present in high density in this area of the brainstem and microinjection of adenosine into these regions can alter blood pressure and HR . However, the responses evoked by adenosine were considerably smaller than those evoked by ATP in the present study. Moreover, in a recent study we have shown that the P1 receptor antagonist 8-phenyltheophylline does not block the excitatory e¡ects of ATP on neurones in the ventral medulla . Suramin has been shown to block ectonucleotidase activity, which may limit its e¡ec-tiveness as an antagonist (Crack et al., 1994; Beukers et al., 1995) . However, this does not alter our interpretations, as we did not observe a consistent or signi¢cant augmentation of the e¡ects of ATP when suramin was microinjected into the VLM. Although non-speci¢c e¡ects of suramin have been reported in rat hippocampal neurones in culture (Nakazawa et al., 1995) , suramin did not block responses to glutamate in the present study.
Our immunohistochemical data illustrate the presence of two suramin-sensitive P2X receptor subtypes, P2X 1 and P2X 2 , in the VLM. We also observed P2X 6 receptors in this region of the medulla, although this subtype is not sensitive to suramin. The P2X 6 subunit is unable to form functional homo-oligomeric assemblies but can co-assemble into hetero-oligomeric assemblies with many other P2X subunits, including the P2X 1 and P2X 2 subtypes (Torres et al., 1999) . Therefore we would suggest that various P2X subunits form heteromeric receptors in the VLM, which could account for the functional responses we observed. In support for this, we have recently shown that co-expression of P2X 2 and P2X 6 subunits in Xenopus oocytes produces a functional heteromeric P2X 2a6 receptor that exhibits suramin sensitivity (King et al., 2000) . We have shown recently that ATP-evoked excitation of inspiratory neurones underlies carbon dioxide-mediated excitation of respiratory activity . Our observation that P2X 2 reactivity was present in the VLM is therefore particularly signi¢cant, since this receptor subtype is known to be highly sensitive to changes in pH (King et al., 1996) .
Our immunohistochemical demonstration that P2X 1 , P2X 2 , P2X 5 and P2X 6 receptor subtypes are present in the VLM is consistent with other studies that have looked for P2X receptors in the CNS (e.g. Yao et al., 2000) . P2X 1 receptors have been recently shown to be present in the cerebellum and P2X 2 receptors in the hypothalamus of the rat (Loesch and Burnstock, 1998; Xiang et al., 1998) . More speci¢cally, a recent study by Kanjhan et al. (1999) reported moderate immunolabelling of P2X 2 subtypes and high levels of P2X 2 receptor mRNA in the VLM. RNA for P2X 6 subunits has also been shown previously to be present in the paragiganticellular nucleus (Collo et al., 1996) , consistent with our ¢ndings. That particular study also showed RNA for P2X 4 in this region and suggested that the P2X 4 and P2X 6 subunits are the most heavily expressed in the brain (Collo et al., 1996) . Consistent with this, our data indicate that the P2X 6 subunit is the most proli¢c P2X subunit in the ventral medulla. A recent study in the rat describes the presence of all six P2X receptors in the VLM (Yao et al., 2000) . In accordance with our data, that study indicated that levels of P2X 3 , P2X 4 and P2X 5 were lower in the VLM than those for P2X 1 , P2X 2 and P2X 6 (Yao et al., 2000) . However, we did not ¢nd any evidence for P2X 3 and P2X 4 labelling in the VLM in this study. We can be sure that these antibodies were e¡ective since we observed P2X 3 labelling in dorsal regions of the brainstem (e.g. nucleus tractus solitarius) and P2X 3 and P2X 4 reactivity in very caudal regions of the ventral medulla and in the region of the nucleus ambiguus. These di¡erences between labelling observed in the present study and that of Yao et al. (2000) are di¤cult to reconcile, but may be due to the use of antibodies from di¡erent sources which may have di¡erent sensitivities (Oglesby et al., 1999; Yao et al., 2000) .
Whilst seven types of P2X receptor proteins have been cloned to date (Ralevic and Burnstock, 1998) , the P2X selectivity of K,L-meATP indicates a possible involvement of P2X 1 and/or P2X 3 receptors. This is supported by our immunohistochemical data, which show that the P2X 1 subtype is localised within this region. This receptor is known to desensitise rapidly (Valera et al., 1994; Chen et al., 1995; Lewis et al., 1995; Collo et al., 1996) , which is consistent with the pronounced and long-lasting desensitisation we observed upon repeated microinjection of K,L-meATP. This contrasts with results obtained in the rabbit, where repeated injections of K,L-meATP produced reproducible cardiovascular responses, without desensitisation (Horiuchi et al., 1999) . This might re£ect species di¡erences in the P2X receptor subtypes localised within the VLM or the formation of heteromultimers, which show di¡erent pharmacological pro¢les. In addition, an involvement of G protein-coupled P2Y receptors for ATP is also possible and cannot be discounted. The fact that the responses to ATP upon repeated microin-jection were reproducible may be due to the rapid breakdown of ATP by ectonucleotidases such that there was minimal opportunity for desensitisation to occur. Di¡er-ential actions at homomeric P2X receptors could also account for the di¡erential susceptibility to desensitisation of responses to ATP and K,L-meATP.
There is evidence of an integration of inputs related to cardiovascular and respiratory activity within the VLM. However, several observations reduce the possibility that the respiratory changes evoked by ATP that we describe are secondary to re£exes evoked as a consequence of cardiovascular changes. Firstly, the inhibitory e¡ects of ATP and K,L-meATP on respiration often preceded any cardiovascular changes. Also the fact that suramin abolished the ATP-evoked apnoea, but did not reduce the hypertensive or tachycardic responses to higher doses of ATP in some cases, and that the respiratory and cardiovascular responses to K,L-meATP desensitised with di¡erent temporal pro¢les might indicate independence of the cardiovascular and respiratory e¡ects of ATP. However, we cannot discount the possibility that di¡er-ent P2 receptor subtypes are responsible for the respiratory and cardiovascular changes, which could also explain the latter results. In light of our previous electrophysiological data, however, we would suggest that ATP could modulate directly, and independently, the respiratory and cardiovascular pathways via actions within the VLM.
CONCLUSION
The results of this study indicate that activation of P2X receptors in the VLM can exert pronounced, independent, e¡ects on the respiratory and cardiovascular systems. Our data also suggest that ATP might have a role in the control of respiratory drive via an action on the respiratory network in this area of the brainstem. We have recently suggested that pH-sensitive ATP receptors in this area of the medulla are involved in carbon dioxide-mediated increases in respiration . Further research is necessary, however, to determine whether P2 receptors in other regions of the brainstem are also involved in determining ventilatory drive during resting conditions and in situations of hypercapnia and hypoxia.
